<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">biob</journal-id><journal-title-group><journal-title xml:lang="ru">Биобезопасность и Биотехнология</journal-title><trans-title-group xml:lang="en"><trans-title>Biosafety and Biotechnology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2707-7241</issn><issn pub-type="epub">2957-5702</issn><publisher><publisher-name>Научно-исследовательский институт проблем биологической безопасности</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">biob-187</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>БИОЛОГИЧЕСКАЯ БЕЗОПАСНОСТЬ И БИОЗАЩИТА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BIOLOGICAL SAFETY AND BIOSECURITY</subject></subj-group></article-categories><title-group><article-title></article-title><trans-title-group xml:lang="en"><trans-title>Antibody response to Trypanosoma evansi in camels of Kazakhstan</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Abay</surname><given-names>Zhandos</given-names></name></name-alternatives><email xlink:type="simple">abaizh097@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="en">KazSRVI LLP<country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>02</month><year>2026</year></pub-date><volume>1</volume><issue>23</issue><issue-title>№23 (2025)</issue-title><elocation-id>187</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Abay Z., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Abay Z.</copyright-holder><copyright-holder xml:lang="en">Abay Z.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.biosafety.kz/jour/article/view/187">https://journal.biosafety.kz/jour/article/view/187</self-uri><trans-abstract xml:lang="en"><p>Surra, caused by Trypanosoma evansi, is a major constraint to camel health and productivity in arid and semi-arid regions. Despite Kazakhstan’s large camel population, peer-reviewed data on surra epidemiology remain scarce.</p><p>A cross-sectional seroepidemiological survey was conducted in two camel-breeding regions of Kazakhstan (Mangystau and Kyzylorda) during 2024 and 2025. Serum samples (n = 2,745 in 2024; n = 2,900 in 2025) were tested for anti-T. evansi antibodies using the complement fixation test (CFT) and the formol gel test (FGT). Seroprevalence was expressed with 95% confidence intervals (CI), and regional/temporal differences were assessed using Pearson’s chi-square test.</p><p>In Mangystau, CFT prevalence decreased from 5.0% (95% CI: 2.15–11.18) in 2024 to 0.78% (95% CI: 0.21–2.82) in 2025 (p = 0.0319), while FGT positivity declined from 65.0% to 5.88% (p &lt; 0.001). Conversely, in Kyzylorda, CFT prevalence increased significantly from 4.0% (95% CI: 3.32–4.82) to 8.88% (95% CI: 7.87–10.01; p &lt; 0.001), whereas FGT values rose slightly from 7.8% to 8.96% without statistical significance (p = 0.1504).</p><p>This study provides the first multi-year evidence of T. evansi circulation in camels in Kazakhstan, revealing contrasting regional dynamics: a sharp decline in Mangystau and a significant increase in Kyzylorda. These findings underscore the heterogeneous nature of surra epidemiology and highlight the need for continued surveillance and combined diagnostic approaches to inform control strategies.</p></trans-abstract></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
